Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Dementia01:30

Dementia

482
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
482
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

744
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
744
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Digital profiling of dysarthria in late- and early-onset Parkinson's disease.

Journal of Parkinson's disease·2026
Same author

The include network: Advancing cross-linguistic equity in brain health research.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Semantic memory navigation in mild cognitive impairment: Automated markers with neural and biofluid correlates.

NeuroImage·2026
Same author

Mind Melodies: An NLP platform to examine music cognition.

Behavior research methods·2026
Same author

Redefining the norms: an interdisciplinary perspective on language testing in multilinguals with acquired and progressive neurogenic disorders.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Social vulnerability shapes deep clinical phenotypes and brain health in aging and dementia across Latin America.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

相关实验视频

Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K

技术与痴呆症 会议前会议

Franco Javier Ferrante1,2,3, Gonzalo Nicolás Pérez1,2,3, Joaquín Ponferrada2

  • 1Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 23, 2025
PubMed
概括

检查仿真语言 (TELL) 2.0 工具包为痴呆症检测提供先进的语音生物标志物分析. 新功能改善了数据收集和分析,提高了早期诊断和不同人群的可访问性.

更多相关视频

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

相关实验视频

Last Updated: Jan 8, 2026

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills
07:31

A Computerized Functional Skills Assessment and Training Program Targeting Technology Based Everyday Functional Skills

Published on: February 13, 2020

7.3K
The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living
08:36

The Immersive Cleveland Clinic Virtual Reality Shopping Platform for the Assessment of Instrumental Activities of Daily Living

Published on: July 28, 2022

4.3K
Transcranial Pulse Stimulation for Alzheimer's Patients
06:08

Transcranial Pulse Stimulation for Alzheimer's Patients

Published on: April 4, 2025

2.0K

科学领域:

  • 神经语言学和计算语言学
  • 生物医学工程和健康信息学
  • 医疗保健中的人工智能

背景情况:

  • 检查真实语言工具包 (TELL) 是一个开发用于收集语音样本和提取语音生物标志物的网络应用程序,用于检测痴呆症.
  • 最初的TELL版本成功地支持了全球范围内的临床评估,包括在资源不足的地区.
  • TELL 2.0 的开发旨在增强原始工具包的功能,引入数据处理和分析的高级功能.

研究的目的:

  • 推出TELL 2.0,这是Toolkit to Examine Lifelike Language的升级版本,它为痴呆症相关语音生物标志物分析提供了增强的功能.
  • 扩大数据收集方法,改进数据处理和分析,完善痴呆症评估的可视化工具.
  • 提高语音生物标志物在痴呆症诊断中的可访问性和临床实用性.

主要方法:

  • TELL 2.0 包含了显著的后端和前端改进,支持基于视频通话和离线数据采集的无损音频和本地转录.
  • 已经实施了一个全面的音频标准化管道,包括振幅规范化,降噪和频道协调.
  • 已经整合了词汇检索,运动语音,语义记忆和自我引用语言的新可解释度量,以及基于机器学习的痴呆症概况预测.

主要成果:

  • 在所有数据收集模式中都显示出一致的音频和转录质量.
  • 新集成的指标准确地将特定神经系统疾病的个体与健康对照区分开来,达到85-93%的准确性.
  • 更新的可视化界面为临床医生提供可操作的见解,将指标与已建立的神经心理框架保持一致.

结论:

  • TELL 2.0显著提高了用于痴呆症评估的语音生物标志物的可访问性和影响,基于其前身的成功.
  • 该工具包代表了痴呆症评估的实用,可扩展和具有成本效益的解决方案,由研究和技术进步驱动.
  • TELL的持续发展旨在将尖端研究转化为用于早期痴呆症检测的广泛应用的临床工具.